Search

Objectives: This study aimed at evaluating the agreement between bioelectrical impedance analysis (BIA) using ABC-02 Medas and A-mode ultrasound (AUS) using BodyMetrix™ BX2000 for fat mass (FM), fat free mass (FFM), and body fat percentage (%BF) in females., Methods: The cross-sectional, single-center, observational study was performed in 206 female subjects aged 18-67 years. The examination program included measurements of body height and weight along with waist, hip circumferences, and body composition analysis. The measurements were performed by ultrasound scanner and bioimpedance analyzer., Results: We found that 20.9% of women were obese based on BMI (≥30 kg/m 2 ), which was significantly lower when using a criterion based on body fat percentage (%BF ≥ 30%) measured with US (53.4%, p = .0056) or BIA (54.8%, p = .0051). At the group level, both methods were found interchangeable and showed practically negligible differences (0.1% for %BF, 0.5 kg for FM, and 0.4 kg for FFM). Agreement analysis conducted in the whole sample revealed a low level of agreement in estimating %BF (CCC =  0.72 0.77 0.82 ) and FFM (CCC =  0.81 0.84 0.86 ), and medium level of agreement in estimating FM (CCC =  0.91 0.93 0.94 ). The level of agreement in estimating %BF and FFM was improved to the medium level with the use of newly generated prediction equations., Conclusion: Thus, the proposed equations can be used for conversion of body composition results obtained by AUS into the BIA data., (© 2023 The Authors. American Journal of Human Biology published by Wiley Periodicals LLC.)

Objective: The aim of the study was to assess the effectiveness and safety of long-term sibutramine therapy in routine clinical practice., Methods: In total, 98,774 patients (82.3% women, 17.7% men) from 142 cities of the Russian Federation were enrolled in the PRIMAVERA program. The mean age of the patients was 39.39 ± 10.38 years, the mean body weight was 99.1 ± 14.28 kg, and the mean BMI was 35.7 ± 4.41 kg/m2. The duration of the sibutramine therapy was determined by physicians: 59.3% of patients took the drug for 6 months, the treatment course of 37.7% of patients was 12 months, and 3% of patients had treatment for 3 months., Results: The BMI reduction correlated with the treatment duration: 3.4 ± 1.53 kg/m2 after 3 months of therapy, 5.4 ± 2.22 kg/m2 after 6 months, and 7.2 ± 3.07 kg/m2 after 12 months. The body weight reduction after 3, 6 and 12 months of treatment was 9.5%, 15.1%, and 19.7%, respectively. The body weight loss associated with sibutramine treatment was accompanied by a slight decrease in blood pressure and did not lead to any significant increases of the heart rate., Conclusions: The results of the PRIMAVERA study confirmed the lack of increased risk of using sibutramine in routine clinical practice in patients without underlying cardiovascular disease and low rate of adverse events., (© 2018 The Author(s) Published by S. Karger GmbH, Freiburg.)

This study estimates diagnostic performance of late-night salivary cortisol (LNSC) as measured by automated electrochemiluminescence immunoassay (ECLIA), evaluates the clinical implication of two consecutive LNSC measurements, and compares its accuracy with enzyme-linked immunosorbent assay (ELISA) and serum cortisol after low-dose dexamethasone suppression test (DST) in obese and overweight patients referred for suspected Cushing's syndrome (CS). One hundred twenty three consecutive obese and overweight referred patients and 98 healthy volunteers provided two saliva samples collected at 23:00 using a Salivette (Sarstedt, Germany), assayed by ECLIA (Cobas e601) and ELISA. The patients underwent DST and were further evaluated until CS was pathologically confirmed (n = 45) or excluded. Diagnostic performance of LNSC was evaluated by receiver operating characteristic (ROC) analysis. The total areas under the curve (AUC) were calculated to compare the different tests. We found that a cut-off value of 9.4 nmol/l can differentiate CS among obese and overweight patients with sensitivity of 84.4 % (95% CI 71.2-92.2), specificity of 92.3 % (95% CI 84.2-96.4), and diagnostic odds ratio of 65.1 (95% CI 20.4-207.6). No difference was found between AUCs from the first, second, and the mean from the two LNSC measurements (ECLIA), LNSC (ELISA), or DST. The single LNSC (ECLIA) and DST improved the sensitivity and specificity for concordant results up to 100 and 97.4 %, respectively. In conclusion, due to its automation and its comparable diagnostic performance, ECLIA is preferable as a first-line LNSC screening test for CS. The initial use of single LNSC followed by DST provides better diagnostic performance for concordant results.